Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy — REALITY

Spinal Muscular Atrophy (SMA) Clinical Trial

Official title:
A Randomized Crossover Pragmatic Study to Evaluate Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Patients With Spinal Muscular Atrophy. REALITY Study.

Status Recruiting

Clinical Trial Summary

The primary objective of the study is to evaluate anxiety level during intrathecal administration (IT) under standard of care (SOC) and virtual reality (VR) conditions using a reliable self-rating scale.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05354414
Study type	Interventional
Source	Biogen
Contact	US Biogen Clinical Trial Center
Phone	866-633-4636
Email	clinicaltrials@biogen.com
Status	Recruiting
Phase	N/A
Start date	May 9, 2022
Completion date	October 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04174157` - Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting	`NCT05115110` - A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy	Phase 2/Phase 3
Terminated	`NCT02876094` - Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy	Phase 2
Recruiting	`NCT05747261` - Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)	Phase 1/Phase 2
Completed	`NCT01736553` - Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
Recruiting	`NCT05335876` - Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials	Phase 3
Withdrawn	`NCT01663584` - Multi-disease Carrier Screening Test Validation	N/A